ストックスクリーナーアプリを入手
1.65
0.00%
0.00
アフターアワーズ：
1.65
前日終値:
$1.65
開ける：
$1.66
24時間の取引高:
47,005
Relative Volume:
0.48
時価総額：
$69.91M
収益：
$6.21M
当期純損益:
$-19.92M
株価収益率:
-1.5714
EPS:
-1.05
ネットキャッシュフロー:
$-16.76M
1週間 パフォーマンス:
+2.48%
1か月 パフォーマンス:
-15.38%
6か月 パフォーマンス:
-32.10%
1年 パフォーマンス:
-38.89%
1日の値動き範囲:
$1.62
$1.683
1週間の範囲:
$1.53
$1.74
52週間の値動き範囲:
$1.51
$3.798
InspireMD Inc. Stock (NSPR) Company Profile
NSPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
1.65 | 69.91M | 6.21M | -19.92M | -16.76M | -1.05 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2016-01-07 | 開始されました | Rodman & Renshaw | Buy |
| 2015-03-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2013-11-26 | 開始されました | Oppenheimer | Outperform |
InspireMD Inc. (NSPR) 最新ニュース
One new InspireMD hire gets 36,118-share inducement grant - Stock Titan
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Performance Recap: Is M tron Industries Inc stock a good dividend stockDividend Hike & Fast Gain Stock Trading Tips - baoquankhu1.vn
Wall Street Recap: Can InspireMD Inc keep up with sector leadersVolume Spike & Consistent Return Strategy Ideas - baoquankhu1.vn
Buyback Watch: Is InspireMD Inc stock risky to hold nowQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Options Flow: Can InspireMD Inc be recession proofJuly 2025 Intraday Action & Fast Moving Stock Watchlists - baoquankhu1.vn
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC) - The Manila Times
InspireMD's CGuard® Prime Carotid Stent System Achieves Landmark Safety and Efficacy Results in C-GUARDIANS Trial Published in JACC - Quiver Quantitative
New carotid stent study reports low stroke rates for high-risk patients - Stock Titan
Chipmakers Recap: Can InspireMD Inc outperform in the next rally2025 Growth vs Value & Daily Chart Pattern Signals - baoquankhu1.vn
Published on: 2026-01-10 23:14:00 - Улправда
InspireMD (NASDAQ:NSPR) shareholders have endured a 81% loss from investing in the stock five years ago - Yahoo Finance
Will InspireMD Inc. (II2) stock outperform value peersProfit Target & Expert Approved Momentum Trade Ideas - Улправда
Why InspireMD Inc. stock could be next big winnerPortfolio Performance Report & Growth Focused Stock Reports - ulpravda.ru
Will InspireMD Inc. stock continue dividend increasesMarket Growth Report & Advanced Technical Signal Analysis - Улправда
Will InspireMD Inc. (II2) stock benefit from sector leadership2025 Macro Impact & Weekly Return Optimization Alerts - Улправда
How InspireMD Inc. stock compares to growth peersTrade Exit Summary & Daily Entry Point Trade Alerts - Улправда
InspireMD (NYSE:NSPR) Trading Down 6.2%Should You Sell? - MarketBeat
InspireMD (NYSE:NSPR) Trading Down 6.2% – Should You Sell? - Defense World
InspireMD (NSPR) price target decreased by 11.11% to 4.08 - MSN
Head to Head Analysis: InspireMD (NYSE:NSPR) versus Minerva Surgical (NASDAQ:UTRS) - Defense World
Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth? - Sahm
Will InspireMD Inc. stock gain from lower inflationWeekly Trade Analysis & Low Risk Entry Point Guides - Улправда
Working capital per share of InspireMD Inc. – DUS:II2 - TradingView — Track All Markets
Can InspireMD Inc. stock hit record highs again2025 Breakouts & Breakdowns & Stepwise Swing Trade Plans - Улправда
Aug Update: Will InspireMD Inc. (II2) stock outperform value peersJuly 2025 Catalysts & Safe Capital Preservation Plans - Улправда
Why InspireMD Inc. stock is considered a top pickJuly 2025 Highlights & Weekly High Return Forecasts - Улправда
Will InspireMD Inc. (II2) stock profit from fiscal stimulusBreakout Watch & Verified Momentum Watchlists - Улправда
InspireMD’s new study on neuroprotection system: A potential game-changer? - MSN
Is InspireMD Inc a good long term investmentREITs Market Trends & Capital Efficiency Improvement - earlytimes.in
InspireMD’s Pivotal Study on CGuard Prime Stent System: A Potential Game-Changer - MSN
InspireMD’s New Study on Neuroprotection System: A Potential Game-Changer? - TipRanks
Aug Selloffs: How InspireMD Inc stock compares to growth peers2025 Institutional Moves & Daily Growth Stock Tips - moha.gov.vn
Head-To-Head Review: Biotricity (NASDAQ:BTCY) versus InspireMD (NYSE:NSPR) - Defense World
Peter A. Soukas Joins InspireMD as Chief Medical Officer - Medical Product Outsourcing
Investment Report: Will InspireMD Inc stock gain from lower inflationWeekly Stock Analysis & Reliable Price Breakout Signals - moha.gov.vn
Total debt per share of InspireMD Inc. – MUN:II2 - TradingView
InspireMD Director Paul Stuka Acquires 10,130 Shares - TradingView
Dir Stuka Buys 10,130 ($18.7K) Of InspireMD Inc [NSPR] - TradingView — Track All Markets
Can InspireMD Inc. (II2) stock survive global slowdownM&A Rumor & High Conviction Trade Alerts - Newser
Is InspireMD Inc. (II2) stock supported by strong fundamentalsWeekly Gains Summary & Weekly Sector Rotation Insights - Newser
InspireMD (NSPR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Financial Contrast: InspireMD (NYSE:NSPR) vs. Biostage (OTCMKTS:BSTG) - Defense World
How InspireMD Inc. stock performs in rate cut cyclesTreasury Yields & Verified Swing Trading Watchlists - BỘ NỘI VỤ
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results - ADVFN
InspireMD (NYSE:NSPR) Shares Up 2%Should You Buy? - MarketBeat
InspireMD announces publication of CREST-2 data in NEJM - MSN
Lake Street Reaffirms Their Buy Rating on InspireMD (NSPR) - The Globe and Mail
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
InspireMD Inc. (NSPR) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
0.96%
大文字化:
|
ボリューム (24 時間):